{
    "clinical_study": {
        "@rank": "5050", 
        "acronym": "PARSPORT-II", 
        "arm_group": {
            "arm_group_label": "oropharyngeal and hypopharyngeal HNSCC", 
            "description": "Intensity Modulated Radiotherapy HPV positive and HPV negative"
        }, 
        "brief_summary": {
            "textblock": "This study is a phase II trial designed to test the feasibility of delivering IMRT to head\n      and neck cancer patients with tumours arising in the midline (oropharynx and hypopharynx),\n      and to assess possible improvement in reducing the incidence of xerostomia with bilateral\n      superficial lobe parotid sparing IMRT."
        }, 
        "brief_title": "A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Oropharyngeal Squamous Cell Cancer", 
            "Hypopharyngeal Squamous Cell Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Squamous Cell", 
                "Neoplasms, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically confirmed locally advanced HNSCC arising from the oropharynx or\n             hypopharynx with high risk of bilateral parapharyngeal space involvement\n\n        Exclusion Criteria:\n\n          -  Patients <18 years old or with a previous malignancy other than non-melanomatous skin\n             cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Midline pharyngeal squamous cell cancers (excluding nasopharyngeal cancers)"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149602", 
            "org_study_id": "CCR 2588"
        }, 
        "intervention": {
            "arm_group_label": "oropharyngeal and hypopharyngeal HNSCC", 
            "description": "Bilateral superficial lobe parotid sparing intensity modulated radiotherapy", 
            "intervention_name": "Intensity modulated radiotherapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "involvement of bilateral parapharyngeal spaces", 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SW3 6JJ"
                }, 
                "name": "Head and Neck Unit, Royal Marsden Hospital"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Phase II Study of Parotid-gland Sparing Intensity-modulated Radiotherapy in Patients With Midline Tumour of the Head and Neck", 
        "overall_official": {
            "affiliation": "The Royal Marsden NHS Foundation Trust", 
            "last_name": "Christopher M Nutting, FRCR", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Royal Marsden Committee of Clinical Research and Local and National Research and Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The proportion of patients reporting grade 2 or more xerostomia using subjective measure on the LENTSOMA late toxicity scoring scale one year after treatment.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149602"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Acute radiation toxicity", 
                "safety_issue": "No", 
                "time_frame": "0-3 months"
            }, 
            {
                "measure": "Late radiation toxicity", 
                "safety_issue": "No", 
                "time_frame": "3-24  months"
            }, 
            {
                "measure": "Survival outcomes for entire cohort and according to HPV status where available : Local control,  Loco regional control,  Loco-regional progression-free survival (LRPFS),  Disease free survival,  Overall survival.", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Royal Marsden NHS Foundation Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Royal Marsden NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2005", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}